Ind-Swift has launched generic formulation of the world’s best selling drug -- Atorvastation -- in UK in collaboration with Wockhardt UK on the first day of its patent expiry. Atorvastation is the world’s best selling drug with the world market size of $16 billion.
The drug went off patent in Europe on May 6, 2012 and taking this opportunity Ind Swift and its EU marketing partner Wockhardt UK launched the generic vwersion of the molecule in UK on the day after its patent expiry.
The product was launched in all its strengths i.e. 10mg, 40mg and 80mg.
Ind-Swift is a fully integrated pharma group. The API required for the product was supplied from the USFDA and MHRA approved plant of Ind-Swif Laboratories and the formulations was manufactured and supplied from the 100% export facility of Ind-Swift located near Derabassi Punjab.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: